Implications of Peginterferon Use in Special Populations Infected with HCV

Kenneth E. Sherman

doi:10.1055/s-2003-41634

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2003; 23: 047-052
DOI: 10.1055/s-2003-41634

Implications of Peginterferon Use in Special Populations Infected with HCV

Kenneth E. Sherman

Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio

Abstract

ABSTRACT

Rapid progress in the treatment of hepatitis C virus (HCV) infection has led to highly successful therapies that lead to viral eradication and sustained viral response in more than 50% of patients. Despite these advances, certain identifiable subpopulations appear to have reduced rates of treatment response. These include patients co-infected with HCV/HIV, alcohol abusers, and African Americans infected with HCV. Using research tools including viral kinetic modeling, factor analysis, and laboratory evaluation of viral and host genomic characteristics, a number of key elements of response have been identified. Examination of special populations reveals that these groups comprise complex mixes of poor prognostic markers. These include both host and viral factors. Use of peginterferons with ribavirin improves response rates in these groups, but does not fully ameliorate the response deficit relative to patients enrolled in typical drug registration clinical trials.

KEYWORDS

HCV - treatment - HIV - alcohol - race - quasispecies - viral load

Volltext

Referenzen

REFERENCES

1 Fried M W, Shiffman M L, Reddy K R. et al . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med . 2002; 347 975-982
2 Manns M P, McHutchison J G, Gordon S C. et al . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet . 2001; 358 958-965
3 Zeuzem S, Herrmann E, Lee J H. et al . Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha-2a. Gastroenterology . 2001; 120 1438-1447
4 Sherman K E, Rouster S D, Chung R T, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis . 2002; 34 831-837
5 Benhamou Y, Bochet M, Di Martino V. et al . Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. The Multivirc Group. Hepatology . 1999; 30 1054-1058
6 Bica I, McGovern B, Dhar R. et al . Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis . 2001; 32 492-497
7 Tedaldi E M, Baker R K, Moorman A C. et al . Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis . 2003; 36 363-367
8 Goedert J J, Eyster M E, Lederman M M. et al . End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood . 2002; 100 1584-1589
9 Sherman K E. Diagnosis and management of the HCV/HIV-coinfected patient. AIDS Clin Care . 2002; 14 39-48
10 Sherman K E, Rouster S D, Horn P S. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus. Clin Infect Dis . 2002; 35 482-487
11 Bonacini M, Govindarajan S, Blatt L M. et al . Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat . 1999; 6 203-208
12 Ragni M V, Bontempo F A. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis . 1999; 180 2027-2029
13 Chung R T, Evans S R, Yang Y. et al . Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS . 2002; 16 1915-1923
14 Alter M J, Kruszon-Moran D, Nainan O V. et al . The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med . 1999; 341 556-562
15 Landau A, Batisse D, Van Huyen P J. et al . Efficacy and safety of combination therapy with interferon alpha-2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS . 2000; 14 839-844
16 Zylberberg H, Benhamou Y, Lagneaux J L. et al . Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut . 2000; 47 694-697
17 Hino K, Yamaguchi Y, Fujiwara D. et al . Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study. J Viral Hepat . 2000; 7 36-42
18 Pawlotsky J M, Pellerin M, Bouvier M. et al . Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J Med Virol . 1998; 54 256-264
19 Sherman K E, Andreatta C, O'Brien J. et al . Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain. Hepatology . 1996; 23 688-694
20 Soriano V, Garcia-Samaniego J, Bravo R. et al . Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis . 1996; 23 585-591
21 Mauss S, Klinker H, Ulmer A. et al . Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection . 1998; 26 16-19
22 Landau A, Batisse D, Piketty C. et al . Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS . 2001; 15 2149-2155
23 Sauleda S, Juarez A, Esteban J I. et al . Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology . 2001; 34 1035-1040
24 Chung R AJ, Alston B, Vallee, M. et al .A randomized controlled trial of pegylated interferon-alfa-2a with ribavirin versus interferon-alfa-2a with ribavirin for treatment of chronic HCV in HIV Co-infection. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 2002
25 Sherman K E, Horn P, Rouster S. et al .HCV RNA kinetic response to PEG-interferon and ribavirin in HCV co-infected patients. Presented at the 9th Conference on Retrovirus and Opportunistic Infections, Seattle, WA, February 2002
26 Perrone C, Carrat F, Sadr F. et al .RIBAVIC trial (ANRS HC02): a controlled randomized trial of pegylated-interferon alfa-2b plus ribavirin versus interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients: preliminary results. Presented at the XIV International Conference on AIDS, Barcelona, Spain, July 7-12, 2002
27 Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet . 2001; 357 280-281
28 Boxwell D FR, Sheman K E. Evidence suggesting mitochondrial toxicity in HIV/HCV co-infected patients receiving ribavirin and certain anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs). Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2003
29 Mendenhall C L, Seeff L, Diehl A M. et al . Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119). Hepatology . 1991; 14 581-589
30 Wiley T E, McCarthy M, Breidi L, Layden T J. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology . 1998; 28 805-809
31 Ohnishi K, Matsuo S, Matsutani K. et al . Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol . 1996; 91 1374-1379
32 Sherman K E, Mendenhall C, Thee D L. et al . Hepatitis C serotypes in nonalcoholic and alcoholic patients. Dig Dis Sci . 1997; 42 2285-2291
33 Sherman K E, Rouster S D, Mendenhall C, Thee D. Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. Hepatology . 1999; 30 265-270
34 Takahashi K, Takahashi T, Takahashi S. et al . Difference in quasispecies of the hypervariable region 1 of hepatitis C virus between alcoholic and non-alcoholic patients. J Gastroenterol Hepatol . 2001; 16 416-423
35 Mendenhall C L, Finkelman F, Means Jr T R. et al . Cytokine response to BCG infection in alcohol-fed mice. Alcohol . 1999; 19 57-63
36 Okazaki T, Yoshihara H, Suzuki K. et al . Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol . 1994; 29 1039-1043
37 Reddy K R, Hoofnagle J H, Tong M J. et al . Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology . 1999; 30 787-793
38 McHutchison J G, Poynard T, Pianko S. et al . The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology . 2000; 119 1317-1323
39 Keenan E, Sherman K E. Complexity and diversity of HCV RNA in African Americans. Hepatology . 2002; 36 207A
40 Kimball P, Elswick R K, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol . 2001; 65 510-516